Hidradenitis suppurativa (HS)
Conditions
Interventions
Observation group:None
Sponsors
The University of Hongkong - Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. > = 18 years old and < = 65 years old, gender is not limited; 2. Meet the diagnostic criteria for hidradenitis suppurativa: (1) Medical history: recurrent painful or purulent skin lesions; (2) Typical clinical manifestations: deep painful nodules, abscesses, sinus tracts, scars in the distribution sites of apocrine sweat glands such as axilla, groin, perineum, perianal area, buttocks and female breast folds; (3) family history of HS; (4) In the early stage of skin lesion histopathology, epidermal cell hyperplasia and hyperkeratosis of hair follicle orifice, and lymphocytes and histiocytes infiltration in the funibulum part of hair follicle can be seen. In the acute stage, a large number of mixed inflammatory cells can be infiltrated in the deep dermis, often extending to the subcutaneous tissue, local abscesses can be seen, and sinus tracts lead to the skin surface, which contain inflammatory cells and residual keratin, common granulation tissue, with inflammatory cells and foreign body giant cells; In the chronic phase, destruction of hair follicles, sebaceous glands, and sweat glands may be seen, with widespread fibrosis. At the same time, HS can be diagnosed if the first two items are met, familial HS can be considered if there is clear existence of item 3, and item 4 has an auxiliary role in the diagnosis and differential diagnosis of this disease. 3. Those who fully understand the content of the trial, voluntarily participate in the trial, and sign the informed consent form; 4. Willing and able to follow planned visits, treatment plans, laboratory tests, and other study procedures.
Exclusion criteria
Exclusion criteria: 1. HS lesion area with tattoos, burns or other diseases with large postoperative scars, which, in the judgment of the investigator, will interfere with the evaluation of response to study drug treatment; 2. Suffering from severe psychiatric illness, or other conditions that may interfere with the performance of clinical trials that affect research compliance; 3. Other conditions that the investigator considers unsuitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| o observe the efficacy of different therapeutic drugs in 1M/3M/6M/12M/ on comorbidities, safety and drug retention rates in real word;Establish a biobank of HS peripheral blood and lesional tissue samples to identify biomarkers for predicting treatment efficacy and prognosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| To explore the potential genetic and immunological mechanisms of different clinical phenotypes; | — |
Countries
China
Contacts
Public ContactZhang Zhenying
The University of Hongkong - Shenzhen Hospital
Outcome results
None listed